Wake Forest University

Johns Hopkins University

Jianfeng Xu

William B Isaacs

Andrew Karim Kader

Siqun Lilly Zheng

Jielin Sun

Patrick C Walsh

Deborah Meyers

Eugene Roland Bleecker

David Herrington

Scott D Cramer

Anuradha Rao

Bao-li Chang

Sigun Zheng

Henrik Grönberg

The present invention provides methods of assessing an individual subject's risk of developing prostate cancer, comprising: a) analyzing a nucleic acid sample obtained from the subject and determining a genotype for the subject at a plurality of biallelic polymorphic loci, wherein each of said plurality has an associated allele and an unassociated allele, wherein the genotype is selected from the group consisting of homozygous for the associated allele, heterozygous, and homozygous for the unassociated allele; and b) calculating a cumulative relative risk (CRR) for the subject based on the genotype determined in step (a). A CRR of greater than 1.00 identifies a subject as having an increased risk of developing prostate cancer and also can identify a subject who is a candidate for early PSA screening, prostate biopsy and/or chemoprevention.

Methods and compositions for correlating genetic markers with prostate cancer risk

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.

Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer

The present invention discloses methods of screening a subject for increased likelihood or risk of certain diseases or disorders. This method comprises detecting the presence or absence of at least one mutation in the MSR1 gene wherein the presence or absence of such mutation indicates an increased risk for certain diseases, such as cancer asthma and/or cardiovascular diseases.

Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease

The present invention includes methods of identifying a subject at risk for increased cellular PSA production and/or prostate cancer by detecting the presence or absence of a genetic polymorphism in the prostate specific antigen gene.

Genetic polymorphisms in the prostate-specific antigen gene promoter

Growing community of inventors

Clemmons, NC, United States of America

Jianfeng Xu